US FDA adds Mahendra Chemicals to import alert "Red List"

By Gareth Macdonald contact

- Last updated on GMT


Related tags: Pharmaceutical drug, Food and drug administration, Fda

Mahendra Chemicals has been banned from shipping drug ingredients made at its plant in Ahmedabad, India to the US.

The active pharmaceutical ingredient (API) manufacturer - whose products include antibiotics and lidocaine - was added to the US Food and Drug Administration’s (FDA) 66-40 import​ alert list – also known as the “Red List” – last Friday.

According to the FDA, companies are subject to an import alert when an “inspection has revealed that a firm is not operating in conformity with current good manufacturing practices (GMP's)​.”

No further details were provided. Mahendra’s inclusion on the import alert means its products can be detained at US borders.

The firm did not respond to a request for comment.

Mahendra's last run-in with the US FDA was in July 2015​ when it received a warning letter detailing problems observed at the Ahmedabad site during an inspection in May 2014.

Related news

Related products

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

TCC TB – a new filler for direct compression

TCC TB – a new filler for direct compression

Jungbunzlauer | 09-Oct-2017 | Technical / White Paper

TCC TB is a tricalcium citrate tetrahydrate designed to function as a direct compression excipient. It combines exceptional compression characteristics,...

Related suppliers